Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Dexcom Reports Third Quarter 2019 Financial Results
Dexcom Reports Third Quarter 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.



Third Quarter 2019 Highlights:




  • Revenue grew 49% versus the same quarter of

BusinessWire_EN 
0 08.11.19
Agilent Named One of Top 10 Best Workplaces in Singapore
Agilent Named One of Top 10 Best Workplaces in Singapore


Agilent Technologies, Inc. (NYSE: A) today announced it has been named among the top 10 Best Workplaces™ in Singapore for 2019 by the Great Place to Work® (GPTW) Institute. Agilent was selected as

BusinessWire_EN 
0 08.11.19
NanoString Technologies Releases Operating Results for Third Quarter of 2019
NanoString Technologies Releases Operating Results for Third Quarter of 2019


NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of

BusinessWire_EN 
0 08.11.19
NanoString Technologies Supports the Human Cell Atlas (HCA) to Enable High-plex Spatial Analysis Across Discovery Programs
NanoString Technologies Supports the Human Cell Atlas (HCA) to Enable High-plex Spatial Analysis Across Discovery Programs


NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will support the Human Cell Atlas

BusinessWire_EN 
0 08.11.19
Chemed Corporation Declares Quarterly Dividend of 32 Cents
Chemed Corporation Declares Quarterly Dividend of 32 Cents


Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 32-cents per share on the Company’s capital stock, payable on December 2, 2019

BusinessWire_EN 
0 08.11.19
CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
In release dated November 4, 2019, the Piper Jaffray Conference webcast date should read: December 4 (instead of December 3), and the Evercore webcast date should read: December 5 (instead of
BusinessWire_EN 
0 08.11.19
Myriad Genetics: Ein wahrhaft hässliches Quartal!
Myriad Genetics: Ein wahrhaft hässliches Quartal!

Zu den größten Verlierern am US-Aktienmarkt zählt heute die Aktie des Biotechunternehmens Myriad Genetics (WKN: 897518). Grund hierfür sind die heute vorgelegten Quartalszahlen, die deutlich

sharedeals 
0 05.11.19
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
eqs_en 
0 04.10.19
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
eqs_en 
0 03.10.19
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
eqs_en 
0 02.10.19
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
eqs_en 
0 01.10.19
Nullzinsen für immer und ewig?
Nullzinsen für immer und ewig?
Das Ende der Nullzinsphase wird immer weiter nach hinten verschoben. Die Europäische Zentralbank (EZB) hat auf ihrer letzten Sitzung von Anfang März den frühestmöglichen Termin von Herbst 2019 auf
finanzjournalisten 
0 26.03.19
EZB bereitet sich auf Konjunktur- und Bankenrettung vor
EZB bereitet sich auf Konjunktur- und Bankenrettung vor
Gleich drei EZB-Ratsmitglieder haben in den letzten Tagen angedeutet, dass die Notenbank mit neuen langfristigen Liquiditätsspritzen der rückläufigen Konjunktur im Euroraum und der Ertragsschwäche
finanzjournalisten 
0 19.02.19
Nullzinsen mindestens bis 2020
Nullzinsen mindestens bis 2020
Die jüngsten Konjunktur- und Inflationsdaten aus Deutschland und der Eurozone machen eine erste Zinserhöhung der EZB noch 2019 immer unwahrscheinlicher. Die deutschen Sparer müssen sich deshalb mit
finanzjournalisten 
0 15.01.19
Die Zinswende lässt noch lange auf sich warten
Die Zinswende lässt noch lange auf sich warten
Seit Ende Januar geht die Sorge um, die Europäische Zentralbank (EZB) werde die Zinsen wegen der starken Konjunktur schneller und stärker anheben als bislang erwartet. Das hat die Anleihenrenditen
finanzjournalisten 
0 14.03.18
Better Stock: Veeva Systems (VEEV) vs. Cerner (CERN)
Better Stock: Veeva Systems (VEEV) vs. Cerner (CERN)
Few industries have given shareholders returns like those of the healthcare sector over the past few decades. Two companies at the forefront of that tide are Veeva Systems (NYSE: VEEV) and Cerner....
TheMotleyFool 
0 21.12.17
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Stocks of companies with solid business models and products that meet needs tend to perform well over the long run. Intuitive Surgical, Inc. (NASDAQ: ISRG) is a good example. The robotic surgical....
TheMotleyFool 
0 21.12.17
The Top 3 Dividend Aristocrats to Watch in 2018
The Top 3 Dividend Aristocrats to Watch in 2018
Income investors rely on the Dividend Aristocrats to provide them with reliable, growing dividend income. These stocks have all raised the amount they pay in dividends year in and year out for at....
TheMotleyFool 
0 19.12.17
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
TheMotleyFool 
0 15.12.17
Civitas Solutions (CIVI) Q4 2017 Earnings Conference Call Transcript
Civitas Solutions (CIVI) Q4 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Civitas Solutions (NYSE: CIVI) Q4 2017 Earnings Conference CallDec. 12, 2017 5:00 p.m. ETOperatorContinue readingSource: Fool.com
TheMotleyFool 
0 14.12.17
Is Illumina, Inc. a Buy?
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
TheMotleyFool 
0 13.12.17
Why Goldman Sachs, Seagate Technology, and Tenet Healthcare Jumped Today
Why Goldman Sachs, Seagate Technology, and Tenet Healthcare Jumped Today
The stock market continued to climb on Tuesday, with the Dow and S&P 500 moving higher to record levels even as the Nasdaq Composite lagged behind. Investors were generally focused on the....
TheMotleyFool 
0 12.12.17
These 3 Stocks Just Raised Their Dividends
These 3 Stocks Just Raised Their Dividends
We're getting down to the wire now, with only a few short weeks until the close of 2017. It was a year nearly full to the brim with dividend raises, so income investors will be sorry to see it....
TheMotleyFool 
0 12.12.17
Enzo Biochem (ENZ) Q1 2018 Earnings Conference Call Transcript
Enzo Biochem (ENZ) Q1 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Enzo Biochem (NYSE: ENZ) Q1 2018 Earnings Conference CallDec. 8, 2017 8:30 a.m. ETOperatorContinue readingSource: Fool.com
TheMotleyFool 
0 11.12.17
Better Buy: Illumina, Inc. vs. Pacific Biosciences
Better Buy: Illumina, Inc. vs. Pacific Biosciences
Rapid advances in the ability to quickly and cheaply sequence DNA and RNA are fueling research in cancer, immunology, complex diseases, forensics, agriculture, and many other areas, while clinical....
TheMotleyFool 
0 11.12.17